[Transferability of trial results into clinical practice: examples taken from paediatric practice]

Johannes Forster1

  • 1St. Josefskrankenhaus (Akademisches Lehrkrankenhaus) und Zentrum für Kinder- und Jugendmedizin, Albert-Ludwigs-Universität Freiburg. Johannes.Forster@rkk-sjk.de

Insights

Chest X-rays are unnecessary for diagnosing uncomplicated lower respiratory tract infections in children, even with respiratory syncytial virus (RSV). Despite evidence, German hospitals continue to use X-rays, potentially for financial gain within the Diagnosis Related Groups system.

Area of Science:

  • Pediatrics
  • Radiology
  • Public Health

Background:

  • Evidence since 2000 indicates chest X-rays are unnecessary for uncomplicated pediatric lower respiratory tract infections.
  • Diagnosis and initial treatment decisions are not influenced by chest X-rays in these cases, particularly for respiratory syncytial virus (RSV) infections.

Purpose of the Study:

  • To investigate the continued use of chest X-rays in infants and children with uncomplicated lower respiratory tract infections in Germany.
  • To explore potential reasons for the discrepancy between evidence-based guidelines and clinical practice.

Main Methods:

  • Analysis of epidemiological data from Germany.
  • Review of diagnostic and therapeutic decision-making processes.
  • Examination of the German Diagnosis Related Groups (DRG) reimbursement system.

Main Results:

  • Epidemiological studies in Germany show ongoing use of chest X-rays for uncomplicated lower respiratory tract infections in children.
  • This practice may be linked to the German DRG system, where pneumonia diagnoses yield higher hospital reimbursement than bronchiolitis.

Conclusions:

  • The continued use of chest X-rays in pediatric lower respiratory tract infections in Germany appears to be driven by financial incentives within the DRG system, rather than clinical necessity.
  • There is a need to align clinical practice with evidence-based guidelines to ensure appropriate resource utilization and patient care.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...